Chelation in metal intoxication-Principles and paradigms

Journal of Trace Elements in Medicine and Biology

Volumn 31, Issue , 2015, Pages 260-266

  Aaseth, Jan ^a   Skaug, Marit Aralt ^b   Cao, Yang ^c   Andersen, Ole ^d  

^a NORWEGIAN KNOWLEDGE CENTRE FOR THE HEALTH SERVICES   (Norway)

^b INLAND NORWAY UNIVERSITY OF APPLIED SCIENCES   (Norway)

^c KAROLINSKA INSTITUTE   (Sweden)

^d ROSKILDE UNIVERSITY   (Denmark)

Author keywords

Deferasirox; Deferiprone; Deferoxamine; DMPS; DMSA

Indexed keywords

ANTIMONY; BISMUTH; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; DIMERCAPROL; EDETATE CALCIUM DISODIUM; EDETIC ACID; PENICILLAMINE; SUCCIMER; TRIENTINE; UNITHIOL; ANTIDOTE; BENZOIC ACID DERIVATIVE; CHELATING AGENT; HEAVY METAL; PYRIDONE DERIVATIVE; TRIAZOLE DERIVATIVE;

ARSENIC POISONING; AUTISM; BINDING AFFINITY; CHELATION THERAPY; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DRUG ABSORPTION; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG USE; FEVER; HEADACHE; HEART PALPITATION; HEAVY METAL POISONING; HUMAN; HYDROPHILICITY; HYPERTENSION; HYPERTRANSAMINASEMIA; IRON OVERLOAD; LEAD POISONING; MACULOPAPULAR RASH; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SWEAT GLAND DISEASE; SYMPTOMATOLOGY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; WILSON DISEASE; DRUG THERAPY; INTOXICATION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTIDOTES; BENZOATES; CHELATING AGENTS; DEFEROXAMINE; HUMANS; METALS, HEAVY; PENICILLAMINE; POISONING; PYRIDONES; SUCCIMER; TRIAZOLES; TRIENTINE; UNITHIOL;

EID: 84940163607     PISSN: 0946672X     EISSN: 18783252     Source Type: Journal    
DOI: 10.1016/j.jtemb.2014.10.001     Document Type: Review

References (82)

1. Peters R.A., Stocken L.A., Thompson R.H. British anti-lewisite (BAL). Nature 1945, 156:616-619.
2. Eagle H., Magnuson H.J., Fleischman R. 2,3 Dithiolpropanol (BAL") as a specific detoxifying agent for arsenic. Fed Proc 1946, 5(1 Pt 2):175.
3. Foreman H, Hamilton JG. The use of chelating agents for accelerating excretion of radioelements. In: University of California Radiation Laboratory UAEC, editor. US Atomic Energy Commission Report. AECD: Oak Ridge, Tenn.; 1951. pp. 1-18.
4. Soares F.A., Farina M., Santos F.W., Souza D., Rocha J.B., Nogueira C.W. Interaction between metals and chelating agents affects glutamate binding on brain synaptic membranes. Neurochem Res 2003, 28(12):1859-1865.
5. Walshe J.M. Penicillamine, a new oral therapy for Wilson's disease. Am J Med 1956, 21(4):487-495.
6. Walshe J.M. Treatment of Wilsons-disease with trientine (Triethylene Tetramine) dihydrochloride. Lancet 1982, 1(8273):643-647.
7. Smith R.S. Iron excretion in thalassaemia major after administration of chelating agents. Br Med J 1962, 2(5319):1577-1580.
8. Kontoghiorghes G.J. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminum chelating drugs. Toxicol Lett 1995, 80(1-3):1-18.
9. Aaseth J. Recent advance in the therapy of metal poisonings with chelating agents. Hum Toxicol 1983, 2(2):257-272.
10. Andersen O., Aaseth J. Molecular mechanisms of in vivo metal chelation: implications for clinical treatment of metal intoxications. Environ Health Perspect 2002, 110(Suppl 5):887-890.
11. Lewis G. Acids and bases. J Franklin Instit 1938, 226(3):293-313.
12. Lippard S.J., Berg J.M., Garner C.D. Principles of bioinorganic chemistry. Nat Product Rep 1995, 12(4):443.
13. Pearson R. Hard and soft acids and bases. J Am Chem Soc 1963, 85(22):3533-3539.
14. Catsch A., Harmuth-Hoene A.E. Pharmacology and therapeutic applications of agents used in heavy-metal poisoning. Pharmacol Ther Pt A 1976, 1(1):1-118.
15. Crisponi G., Nurchi V.M., Crespo-Alonso M., Toso L. Chelating agents for metal intoxication. Curr Med Chem 2012, 19(17):2794-2815.
16. Andersen O. Principles and recent developments in chelation treatment of metal intoxication. Chem Rev 1999, 99(9):2683-2710.
17. Modell W., Gold H., Cattell M. Clinical uses of 2,3-dimercaptopropanol (BAL). IV. Pharmacologic observations on BAL by intramuscular injection in man. J Clin Invest 1946, 25(4):480-487.
18. Vilensky J.A., Redman K. British anti-Lewisite (dimercaprol): an amazing history. Ann Emerg Med 2003, 41(3):378-383.
19. Berlin M., Ullberg S. Increased uptake of mercury in mouse brain caused by 2,3-dimercaptopropanol. Nature 1963, 197:84-85.
20. Aaseth J. The effect of mercaptodextran on distribution and toxicity of mercury in mice. Acta Pharmacol Tox 1973, 32(6):430-441.
21. Schafer B., Kreppel H., Reichl F.X., Fichtl B., Forth W. Effect of oral treatment with Bal, DMPS or DMSA arsenic in organs of mice injected with arsenic trioxide. Arch Toxicol Suppl 1991, 14:228-230.
22. Germuth F.J., Eagle H. The efficacy of BAL (2,3-dimercaptopropanol) in the treatment of experimental lead poisoning in rabbits. J Pharmacol Exp Ther 1948, 92(4):397-410.
23. Ding G.S., Liang Y.Y. Antidotal effects of dimercaptosuccinic acid. J Appl Toxicol 1991, 11(1):7-14.
24. Li D., An D., Zhou Y., Liu J., Waalkes M.P. Current status and prevention strategy for coal-arsenic poisoning in Guizhou, China. J Health Popul Nutr 2006, 24(3):273-276.
25. Dart R.C., Hurlbut K.M., Maiorino R.M., Mayersohn M., Aposhian H.V., Hassen L.V.B. Pharmacokinetics of meso-2,3-dimercaptosuccinic acid in patients with lead-poisoning and in healthy-adults. J Pediatr-Us 1994, 125(2):309-316.
26. Wiedemann P., Fichtl B., Szinicz L. Pharmacokinetics of C-14-labeled Dmps (sodium-1,3 C-14-2,3-dimercaptopropane-1-Sulphonate) in beagle dogs. Biopharm Drug Dispos 1982, 3(3):267-274.
27. Maiorino R.M., Akins J.M., Blaha K., Carter D.E., Aposhian H.V. Determination and metabolism of dithiol chelating-agents .10. In humans, meso-2,3-dimercaptosuccinic acid is bound to plasma-proteins via mixed disulfide formation. J Pharmacol Exp Ther 1990, 254(2):570-577.
28. Maiorino R.M., Dart R.C., Carter D.E., Aposhian H.V. Determination and metabolism of dithiol chelating-agents. 12. Metabolism and pharmacokinetics of sodium 2,3-dimercaptopropane-1-sulfonate in humans. J Pharmacol Exp Ther 1991, 259(2):808-814.
29. Dietrich K., Ware J., Salganik M., Radcliffe J., Rogan W., Rhoads G., et al. Effect of chelation therapy on the neuropsychological and behavioral development of lead-exposed children after school entry. Pediatrics 2004, 114(1):19-26.
30. Cao Y., Chen A.M., Jones R.L., Radcliffe J., Dietrich K.N., Caldwell K.L., et al. Efficacy of succimer chelation of mercury at background exposures in toddlers: a randomized trial. J Pediatr-Us 2011, 158(3). 480-U164.
31. Bernard S., Enayati A., Redwood L., Roger H., Binstock T. Autism: a novel form of mercury poisoning. Med Hypotheses 2001, 56(4):462-471.
32. Kidd P.M. Autism, an extreme challenge to integrative medicine. Part 2: medical management. Altern Med Rev: J Clin Ther 2002, 7(6):472-499.
33. Aschner M., Walker S.J. The neuropathogenesis of mercury toxicity. Mol Psychiatr 2002, 7(Suppl 2):S40-S41.
34. Wecker L., Miller S.B., Cochran S.R., Dugger D.L., Johnson W.D. Trace element concentrations in hair from autistic children. J Ment Defic Res 1985, 29(Pt 1):15-22.
35. Davis T.N., O'Reilly M., Kang S., Lang R., Rispoli M., Sigafoos J., et al. Chelation treatment for autism spectrum disorders: a systematic review. Res Autism Spectr Disord 2013, 7(1):49-55.
36. Crisponi G., Nurchi V.M., Lachowicz J.I., Crespo-Alonso M., Zoroddu M.A., Peana M. Kill or cure: misuse of chelation therapy for human diseases. Coord Chem Rev 2014, [in press]. 10.1016/j.ccr.2014.04.023.
37. Cao Y., Skaug M.A., Andersen O., Aaseth J. Chelation therapy in intoxications with mercury, lead and copper. J Trace Elem Med Biol: Organ Soc Miner Trace Elem 2014.
38. Sengupta M., Mukherjee A., Hossain M., Ahamed S., Rahman M., Lodh D., et al. Groundwater arsenic contamination in the Ganga-Padma-Meghna-Brahmaputra plain of India and Bangladesh. Arch Environ Health 2003;Nov, 58(11):701-702.
39. Guha Mazumder D.N., De B.K., Santra A., Ghosh N., Das S., Lahiri S., et al. Randomized placebo-controlled trial of 2,3-dimercapto-1-propanesulfonate (DMPS) in therapy of chronic arsenicosis due to drinking arsenic-contaminated water. J Toxicol Clin Toxicol 2001, 39(7):665-674.
40. Guha Mazumder D.N., Ghoshal U.C., Saha J., Santra A., De B.K., Chatterjee A., et al. Randomized placebo-controlled trial of 2,3-dimercaptosuccinic acid in therapy of chronic arsenicosis due to drinking arsenic-contaminated subsoil water. J Toxicol Clin Toxicol 1998, 36(7):683-690.
41. Basinger M., Jones M. Structural requirements for chelate antidotal efficacy in acute antimony(III) intoxication. Res Commun Chem Pathol Pharmacol 1981, 32(2):355-363.
42. Andersen O., Aaseth J., Fischer A. Clinical chelation: treatment of metal intoxications: principles and recent developments. Metals essentiality, toxicity and selectivity 2005, 48-113. ABD Publishers, Jaipur, India. Prakash AFaR (Ed.).
43. McFee R.B., Leikin J.B. Death by polonium-210: lessons learned from the murder of former Soviet spy Alexander Litvinenko. Semin Diagn Pathol 2009, 26(1):61-67.
44. Nemhauser J.B. The polonium-210 public health assessment: the need for medical toxicology expertise in radiation terrorism events. J Med Toxicol 2010, 6(3):355-359.
45. Hursh J.B. The effect of BAL on the excretion and tissue distribution of polonium in rats. J Pharmacol Exp Ther 1951, 103(4):450-459.
46. Erleskova E. [Characteristics of the distribution and excretion of polonium in animals following the administration of unithiol]. Med Radiol (Mosk) 1959, 4:54-60.
47. Rencova J., Volf V., Jones M.M., Singh P.K. Decorporation of polonium from rats by new chelating-agents. Radiat Prot Dosim 1994, 53(1-4):311-313.
48. Seely D.M., Wu P., Mills E.J. EDTA chelation therapy for cardiovascular disease: a systematic review. BMC Cardiovasc Disord 2005, 5:32.
49. Flora G.J., Seth P.K., Prakash A.O., Mathur R. Therapeutic efficacy of combined meso 2,3-dimercaptosuccinic acid and calcium disodium edetate treatment during acute lead intoxication in rats. Human Exp Toxicol 1995, 14(5):410-413.
50. Crinnion W.J. EDTA redistribution of lead and cadmium into the soft tissues in a human with a high lead burden - should DMSA always be used to follow EDTA in such cases?. Altern Med Rev: J Clin Ther 2011, 16(2):109-112.
51. Tandon S.K., Singh S., Jain V.K. Efficacy of combined chelation in lead intoxication. Chem Res Toxicol 1994, 7(5):585-589.
52. Jiang Y.M., Mo X.A., Du F.Q., Fu X., Zhu X.Y., Gao H.Y., et al. Effective treatment of manganese-induced occupational Parkinsonism with p-aminosalicylic acid: a case of 17-year follow-up study. J Occup Environ Med/Am College Occup Environ Med 2006, 48(6):644-649.
53. Zheng W., Jiang Y.M., Zhang Y., Jiang W., Wang X., Cowan D.M. Chelation therapy of manganese intoxication with para-aminosalicylic acid (PAS) in Sprague-Dawley rats. Neurotoxicology 2009, 30(2):240-248.
54. Munthe E., Jellum E., Aaseth J. Some aspects of the mechanism of action of penicillamine in rheumatoid-arthritis. Scand J Rheumatol 1979, 6-12.
55. Netter P., Bannwarth B., Pere P., Nicolas A. Clinical pharmacokinetics of d-penicillamine. Clin Pharmacokinet 1987, 13(5):317-333.
56. Gibbs K., Walshe J. The metabolism of trientine: animal studies. Orphan diseases and orphan drugs 1986, Manchester University Press. I. Scheinberg, J. Walshe (Eds.).
57. Lu J. Triethylenetetramine pharmacology and its clinical applications. Mol Cancer Ther 2010, 9(9):2458-2467.
58. Ren M.S., Zhang Z., Wu J.X., Li F., Xue B.C., Yang R.M. Comparison of long lasting therapeutic effects between succimer and penicillamine on hepatolenticular degeneration. World J Gastroenterol 1998, 4(6):530-532.
59. Bush A.I. The metal theory of Alzheimer's disease. J Alzheimers Dis 2013, 33(Suppl 1):S277-S281.
60. Brewer G.J. Metals in the causation and treatment of Wilson's disease and Alzheimer's disease, and copper lowering therapy in medicine. Inorg Chim Acta 2012, 393:135-141.
61. Piga A., Gaglioti C., Fogliacco E., Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003, 88(5):489-496.
62. Maggio A., Vitrano A., Capra M., Cuccia L., Gagliardotto F., Filosa A., et al. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells Mol Dis 2009, 42(3):247-251.
63. Mourad F.H., Hoffbrand A.V., Sheikh-Taha M., Koussa S., Khoriaty A.I., Taher A. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol 2003, 121(1):187-189.
64. Kolnagou A., Kleanthous M., Kontoghiorghes G.J. Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy. Hemoglobin 2011, 35(3):186-198.
65. Nisbet-Brown E., Olivieri N.F., Giardina P.J., Grady R.W., Neufeld E.J., Sechaud R., et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003, 361(9369):1597-1602.
66. Piga A., Galanello R., Cappellini M.D., Forni G., Opitz H., Ford J.M., et al. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy. Blood 2002, 100(11):5A.
67. Galanello R., Piga A., Alberti D., Rouan M.C., Bigler H., Sechaud R. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol 2003, 43(6):565-572.
68. Pennell D.J., Porter J.B., Cappellini M.D., El-Beshlawy A., Chan L.L., Aydinok Y., et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood 2010, 115(12):2364-2371.
69. Cappellini M.D. Iron-chelating therapy with the new oral agent ICL670 (Exjadee((R))). Best Pract Res Cl Ha 2005, 18(2):289-298.
70. Pepe A., Meloni A., Capra M., Cianciulli P., Prossomariti L., Malaventura C., et al. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica 2011, 96(1):41-47.
71. Kontoghiorghes G.J. Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities. Expert Opin Drug Saf 2007, 6(3):235-239.
72. Xia S., Zhang W., Huang L., Jiang H. Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials. PLoS One 2013, 8(12):e82662.
73. Kakhlon O., Breuer W., Munnich A., Cabantchik Z.I. Iron redistribution as a therapeutic strategy for treating diseases of localized iron accumulation. Can J Physiol Pharmacol 2010, 88(3):187-196.
74. Weinreb O., Mandel S., Youdim M.B., Amit T. Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators. Free Radic Biol Med 2013, 62:52-64.
75. Wallis L.I., Paley M.N.J., Graham J.M., Grunewald R.A., Wignall E.L., Joy H.M., et al. MRI assessment of basal ganglia iron deposition in parkinson's disease. J Magn Reson Imaging 2008, 28(5):1061-1067.
76. Kontoghiorghes G.J. The proceedings of the 20th International Conference on Chelation held in the USA: advances on new and old chelation therapies. Toxicol Mech Methods 2013, 23(1):1-4.
77. Merlot A.M., Kalinowski D.S., Richardson D.R. Novel chelators for cancer treatment: where are we now?. Antioxid Redox Signal 2013, 18(8):973-1006.
78. Zvirblis P., Ellin R.I. Acute systemic toxicity of pure dimercaprol and trimercaptopropane. Toxicol Appl Pharmacol 1976, 36(2):297-299.
79. Aposhian H.V., Carter D.E., Hoover T.D., Hsu C.A., Maiorino R.M., Stine E. DMSA, DMPS, and DMPA-as arsenic antidotes. Fundam Appl Toxicol 1984, 4(2 Pt 2):S58-S70.
80. Lewis R, Tatken R. Registry of toxic effects of chemical substances. Services UDoHaH, editor. 1980.
81. Cantilena L., Klaassen C. Comparison of the effectiveness of several chelators after single administration on the toxicity, excretion, and distribution of cadmium. Toxicol Appl Pharmacol 1981, 58(3):452-460.
82. Ciba-Geygy. Product monograph on desferrioxamine. 1994.